FXR agonism has shown benefit in several preclinical models of NAFLD/NASH, inducing metabolic effects that reduce steatosis and inflammation (Figure 3) [250]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.